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ABSTRACT
p53 maintains genome integrity by initiating the
transcription of genes involved in cell-cycle arrest,
senescence, apoptosis and DNA repair. The activity
of p53 is regulated by both post-translational
modifications and protein–protein interactions.
p53 that has been phosphorylated at S366, S378
and T387 binds 14-3-3 proteins in vitro. Here, we
show that these sites are potential 14-3-3 binding
sites in vivo. Epsilon (e) and gamma (c) isoforms
required phosphorylation at either of these sites
for efficient interaction with p53, while for sigma
(p) and tau (q) these sites are dispensable. Further,
p and q bound more weakly to p53 C-terminal
phosphopeptides than did e and c. However, the
four isoforms bound tightly to di-phosphorylated
p53 C-terminal peptides than did the mono-
phosphorylated counterparts. Interestingly, all the
isoforms studied transcriptionally activated wild-
type p53. p and q stabilized p53 levels in cells,
while e and c stimulated p53-DNA binding activity
in vitro. Overall, the results suggest that structurally
and functionally similar 14-3-3 isoforms may exert
their regulatory potential on p53 through different
mechanisms. We discuss the isoform-specific
roles of 14-3-3in p53 stabilization and activation of
specific-DNA binding.
INTRODUCTION
The tumour suppressor p53 plays a vital role in the tran-
scription of target genes that are involved in cell-cycle
arrest, DNA repair and apoptosis (1,2). Upon stress
stimuli, p53 is activated and stabilized as a sequence-
speciﬁc transcription factor and its activity is often
regulated by various interacting partners (3). The 393
amino acid long protein has an intrinsically disordered
N-terminal transactivation domain (p53 TAD), a
structured DNA binding core domain (the carrier of
hot-spot mutations in cancer), a tetramerization domain
(important for cooperative DNA binding) and a
C-terminal domain (p53 CTD, negatively regulates
speciﬁc DNA binding of p53) (4).
The intrinsically unstructured p53 TAD and p53 CTD
are target sites for various post-translational modiﬁcations
such as phosphorylation and acetylation (5,6). p53 CTD is
acetylated at K370, K372, K381 and K382 by p300/CBP
and these acetylations have been shown to decrease the
non-speciﬁc DNA binding of p53 CTD in vitro (7).
Phosphorylation of p53 at S15, T18, S20 upregulates its
transcriptional activity by directly stabilizing it against
MDM2-mediated degradation (8,9). Several sites are
also phosphorylated in the p53 CTD, particularly, S366,
T377, S378, T387 and S392 (10,11). In response to DNA
damage, ATM kinase, the gene mutated in ataxia
telangiectasia, activates checkpoint kinases Chk1 and
Chk2, which phosphorylate p53 at multiple sites, in
particular, S313, S314, S366, T377, S378 and T387.
Mutation of these phosphorylation sites has diﬀerential
eﬀects on the acetylation of p53 (10). Phosphorylation at
S378 and dephosphorylation at S376 are important for
14-3-3 to activate human p53 (12). However, two addi-
tional sites, S366 and T387 have been identiﬁed on
human p53 CTD in vitro that could be additional
binding sites for 14-3-3 proteins (13).
The 14-3-3 family of proteins is involved in diverse
functions such as apoptosis, cell-cycle checkpoints
and signal transduction pathways (14). The 14-3-3
proteins are dimeric and bind protein targets following
their serine/threonine phosphorylation at a consensus
motif (15,16). In humans, seven diﬀerent isoforms have
been identiﬁed: b, g, e, g, t (also referred as y), z and s.
While most of these isoforms are expressed in all tissues,
s is restricted to epithelial cells (17). The dimeric protein
has two binding pockets for phosphoserine- or
phosphothreonine- containing motifs. While canonical
binding motifs referred to as mode 1 [R(S/Ar)XpS
(LEAM)P] and mode 2 [RX(Y/F)XpS[LEAM]P) have
been identiﬁed for 14-3-3, these proteins interact with
targets that deviate signiﬁcantly from the deﬁned motif
(15,18,19). 14-3-3s has been most widely studied of
all, because of its direct linkage to cancer (17). 14-3-3s
is a target gene of p53 and up-regulation of s leads to
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3-3s has been proposed, whereby 14-3-3s stabilizes p53
from MDM2-mediated degradation (21,22).
In the present study, systematic mutational studies
were carried out to probe the importance of three
p53 phosphorylation sites (S366, S378 and T387) for
four isoforms of 14-3-3: g, e, t and s. Nickel pull-down
assays and immunoprecipitation experiments were carried
out to identify p53 interactions with diﬀerent 14-3-3
isoforms. Both the in vitro and the in vivo results agree
well while raising the possibility of additional binding
sites for 14-3-3 t and s. Since the false positive rates
are higher in pull-down assays, we carried out ﬂuorescence
binding measurements on p53 CTD phosphopeptides
for the four isoforms. The experiments conﬁrmed
that the isoforms bind p53 CTD but with varying
aﬃnities. We discuss the possible modulatory role
exerted by 14-3-3 in regulating p53’s transcriptional
activity.
MATERIALS AND METHODS
Plasmid construction
For bacterial expression, 14-3-3 isoforms were cloned
using BamHI and EcoRI sites into a pET24a vector con-
taining His-lipoyl and Tev protease sites. For transient
transfection experiments, cDNAs encoding human p53
and various mutant forms were cloned into pCDNA3.1
(+) (Clontech). cDNAs of human 14-3-3 isoforms were
ampliﬁed and cloned into pCDNA3.1 (+) vector using
BamHI and EcoRI sites. All constructed plasmids were
veriﬁed by sequencing.
Transfection of cell lines and luciferase assays
H1299 (p53 null) cells stably integrated with the p21-
luciferase reporter were grown in RPMI 1640 medium
(Invitrogen) supplemented with 10% fetal calf serum
and G418. Twenty four hours before transfection, the
cells were subcultured from conﬂuence to a 1:6 dilution
into 6-well plates. For transfections for luciferase assays,
each well received 0.1mg of pCMV-Renilla (Promega),
0.2 mg of pcDNA-p53 and various amounts of pcDNA-
14-3-3 plasmids as indicated in the ﬁgure legends. The
DNA amount was normalized using empty pcDNA3.1
vector. Transfection was performed with Lipofectamine
2000 (Invitrogen) according to the manufacturer’s
instructions. Cells were treated with 0.5mM CPT or
DMSO immediately after transfection. Twenty four
hours after drug treatment, cells were washed twice with
PBS and lysed using RIPA buﬀer (150mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS and
50mM Tris–HCl at pH 8.0) to which a complete
EDTA-free protease inhibitor tablet (Roche) had been
added. Luciferase assays were performed with the Dual-
Luciferase Reporter Assay system (Promega) in accor-
dance with the manufacturer’s instructions. Wells were
prepared in triplicate, and error bars represent 1 SD.
H1299 cells expressing inducible-wild type p53 (a kind
gift from Carol Prives, Columbia University, NY, USA)
under the control of a tetracycline-regulated promoter
were maintained in RPMI 1640 (Invitrogen) containing
10% FCS, 250mg/ml G418, 2mg/ml puromycin and
4.5mg/ml tetracycline (tet) as described (23–25).
Transfections were carried out in medium containing tet
and cells were induced to express p53 by placing them
in tet-free medium. Control cells were maintained
in medium containing tet. After 24h of induction, cells
were placed in medium containing tet and CPT (or
DMSO). After 24h of CPT treatment, lysates were
prepared for immunoblot or luciferase assays.
Immunoprecipitation and western blots
For immunoprecipitations, transfected cells from three
wells of a 6-well plate were washed twice in cold PBS
and scraped into 400ml of RIPA buﬀer containing
a complete EDTA-free protease inhibitor mix. After
removing debris by centrifugation, the pre-cleared
extract was incubated overnight with 30mg of 14-3-3
isoform-speciﬁc antibodies [s: ab60311 (Abcam),
t: SC-732, g: SC-731, e: SC-1020, (Santa Cruz
Biotechnology, Santa Cruz, CA, USA)] and 15mlo f
protein G agarose. Beads were collected by centrifugation
and washed three times in 10S buﬀer (50mM HEPES,
pH 7.5, 150mM NaCl, 0.2% NP-40, 0.1% Triton X-100
and 0.01% SDS). Bound proteins were eluted in 60ml
SDS–PAGE sample buﬀer containing 3mM DTT.
Eluted proteins were separated on 4–12% SDS–PAGE
gels and electroblotted onto nitrocellulose membranes.
Proteins were detected using mouse anti-p53 (PAb1801)
antibodies. Horseradish peroxidase (HRP)-conjugated
goat anti-mouse was used at dilution of 1:5000. ECL
western blotting detection kit (Amersham Pharmacia
Biotech, Sweden) was used for protein detection.
Immunoprecipitation using phospho-speciﬁc antibodies
for pS366, pS378 and pT387 (generous gift from Sheau-
Yann Shieh, Taiwan) were carried out as described
above (10).
Protein expression and puriﬁcation
Protein expression was carried out as described earlier
(13). Brieﬂy, BL21 cells were transformed with 14-3-3
expression plasmids. A single colony was used to inoculate
the overnight culture. Three litres of expression cultures at
37 C and 250r.p.m. were induced with 0.8mM IPTG
at an A600  0.6 and allowed to express for 16h at 20 C.
The cells were harvested and sonicated in cell-cracking
buﬀer of 50mM sodium phosphate, pH 7.5, 300mM
NaCl, 14mM b-mercaptoethanol. After centrifugation,
the soluble fraction was loaded onto a Hi-trap Ni
column and eluted with a 10–250mM imidazole gradient
over 10-column volumes. The pooled fractions were
digested with Tev protease overnight at 4 C and then
diluted with equilibration buﬀer followed by loading
onto the Ni column. The ﬂow-through was concentrated
and further puriﬁed on a Superdex 75 26/60 preparative
gel ﬁltration (Amersham Biosciences, UK). The proteins
were >95% pure as judged by SDS–PAGE analysis.
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Twenty microlitres of Ni-nitrilotriacetic acid (NTA-
Sepharose) beads (Qiagen) were incubated with 5mg
His6,o r5 mg of His6-14-3-3 isoforms in Ni binding
buﬀer (25mM imidazole, 25mM Tris–HCl, 150mM
NaCl, 3mM DTT, pH 7.4, 0.1% NP-40) for 1h
followed by rocking with the cell lysate extract at 4 C
for 4h. After gentle centrifugation, the beads were
washed ﬁve times with Ni binding buﬀer. Bound
proteins were eluted in 60ml of SDS–PAGE sample
buﬀer containing 250mM imidazole and 5mM DTT
and were separated in SDS–PAGE gels. p53 was
detected by immunoblotting using PAb1801 (Abcam).
Fluorescence anisotropy and EMSA
Peptides were synthesized on a pioneer peptide synthesizer
(Applied Biosystems, UK) as described (13,26).
Measurements were recorded on FluoroMax-3 spectro-
ﬂuorimeter (Jobin Yvon-Horiba) equipped with a
Hamilton Microlab Titrator, at 20 C in buﬀer containing
20mM HEPES, pH 7.2, 150mM NaCl and 2mM DTT.
14-3-3 protein was titrated into a cuvette containing either
1.2-ml ﬂuorescein-labelled peptides (initial concentration
50nM) as described previously (13). Manual titrations
were carried out for mono-phosphorylated p53 CTD
peptides, while automatic titrations were performed on
all other peptides. Excitation/emission wave-lengths used
for ﬂuorescein were 480/530nm. Data analysis was per-
formed using KaleidaGraph software with a simple one-
state binding model (13).
EMSA experiments were carried out as described (13).
p21 dsDNA (8mM) 50-CGCGAACATGTTCGAACCAT
GTTCGCG-30 labelled with ﬂuorescein at the 50-end was
used in experiments. Phosphorylation of p53 using Chk1
and Chk2 was carried out as described earlier (13).
Phosphorylated p53 was incubated with diﬀerent
amounts of the 14-3-3 isoforms for 1h followed by
addition of p21 DNA for 30min in 20mM HEPES,
150mM NaCl, 3mM DTT, 10% glycerol, pH 7.2. Gel
images were acquired using a with Typhoon scanner
(GE Healthcare) and analysed with ImageQuant TL
software (GE Healthcare).
Circular dichroism and DSC measurements
Thermal denaturation of 14-3-3 isoforms was measured
by far-UV CD (222nm) using a Jasco J815 spectropo-
larimeter and data were ﬁtted to a two-state transition
as described. Two point ﬁve micromolars of 14-3-3
isoforms were used in a buﬀer containing 20mM
HEPES, 150mM NaCl, 3mM DTE, pH 7.2. Data were
recorded in a temperature range of 2 Ct o9 8  C with
1 C/min temperature gradient and 4s of response.
Isosbestic titration was carried out similarly by recording
the wavelength scan at various temperatures.
Calorimetric measurements were performed by using
a VP-DSC microcalorimeter (MicroCal), equipped
with an AutoSampler. Scans were obtained at a protein
concentration of 100mM, in buﬀer containing 20mM
HEPES, 150mM NaCl, 3mM DTE, pH 7.2. A scan rate
of 250 C/h was used, over a temperature range from 10 C
to 90 C. The reversibility of the transition was checked
by cooling and reheating the same sample. Results from
the DSC measurements were analysed with the Origin
7.0 software from MicroCal.
RESULTS
Thermodynamic stabilities of 14-3-3 isoforms
Five isoforms of 14-3-3 (g, b, e, t, s) were recombinantly
expressed in Escherichia coli and puriﬁed. We measured
the equilibrium stabilities before carrying out p53-14-3-3
in vitro binding studies in order to conﬁrm that 14-3-3 is
stable during the experiments.
The crystal structures of 14-3-3 proteins are all
homodimers (19). Previous reports on dimerization equi-
libria studies showed e, t and g isoforms are dimeric,
while b was found to be in monomer-dimer equilibrium
(27). e has a higher preference to form heterodimers. Each
monomer of 14-3-3 consists of a bundle of nine a-helices.
Circular dichroism (CD) was used to monitor the thermal
unfolding of the helices at 222nm (Figure 1A). The
isoforms exhibited a narrow stability range with melting
temperatures (Tm) ranging from 57 Ct o6 4  C. s was the
most stable of the isoforms studied, with an apparent Tm
of 64.4 C, while b had the lowest Tm of 57.8 C. Of the ﬁve
isoforms studied, only the s isoform exhibited reversible
folding behaviour and showed isosbestic point indicative
of two-state folding (Figure 1B). We also used diﬀerential
scanning calorimetry (DSC) to measure the melting
temperature of diﬀerent 14-3-3 isoforms (Figure 1C). A
systematic increase in the Tm was observed in DSC as
compared to CD, and this is probably due to the
oligomeric state of 14-3-3. Oligomeric proteins exhibit
concentration dependent Tm shifts in DSC. The 14-3-3
isoforms showed a similar trend in melting temperatures
as measured by both CD and DSC. Table 1 lists the Tm
values of the 14-3-3 isoforms measured using CD and
DSC. The results conﬁrmed that the 14-3-3 isoforms are
stable enough for in vitro p53/14-3-3 interactions studies to
be carried out.
Activated p53 interacts with 14-3-3 c, e, q and p
We previously identiﬁed the binding of 14-3-3 g and e to
p53 phosphorylated at S366, S378 and T387 using peptide
screening (13). In order to identify whether 14-3-3 binds to
these phosphorylation sites in vitro and if additional
binding sites exist in p53, we carried out Nickel pull-
down assays. H1299 (p53-null) cell lines were transfected
with wild-type (WT) p53 or alanine mutants of the corre-
sponding phosphorylation sites: S366A, S378A, T387A
and the triple mutant 3A (S366A/S378A/T387A). Cells
were treated with camptothecin (CPT), a topoisomerase
inhibitor or DMSO (control) 24h after transfection. CPT
treatment induces double stranded DNA breaks,
activating the ATM and Chk1/Chk2 pathway. The
Chk1/Chk2 kinases phosphorylate p53 at S366, S378
and T387 (10). In order to conﬁrm that p53 is phos-
phorylated at these residues, cell lysates were immunopre-
cipitated with anti- pS366, pS378 and pS387 speciﬁc
Nucleic AcidsResearch, 2010, Vol.38,No. 3 895antibodies and immunoblotted for p53 (Figure 2A).
Western blots conﬁrmed that p53 is phosphorylated at
these residues upon DNA damage. The speciﬁcity of the
antibodies has been validated elsewhere (10).
For the Ni-pull down assays, cell lysates were incubated
with His tagged-14-3-3 bound to the Ni-NTA beads and
immunoblotted for p53. The isoforms, t, s, g and e but
not b were identiﬁed to form a complex with p53.
Interestingly, the four 14-3-3 isoforms also bound to all
the single Ala mutants. However, t and s isoforms bound
strongly to the p53 3A mutant, whereas binding by g and e
was weak or barely detectable. This experiment indicated t
and s might have additional interaction sites in activated
p53 (Figure 2B).
Having identiﬁed the isoforms that bind p53 in vitro,w e
investigated whether these isoforms could also interact
with p53 in vivo. Immunoprecipitation results conﬁrmed
the observations made from the in vitro pull-down assays,
with t and s binding to all the mutant forms while g and e
failed to bind the 3A mutant (Figure 2C). We could not
detect signiﬁcant endogeneous levels of 14-3-3 g, e, and t
in H1299 cell lines although the basal level of the s
isoform could be detected on western blots, but upon
transfection, both p53 and the 14-3-3 isoforms are over-
expressed. We observed similar p53 levels in cells treated
with or without CPT (Supplementary Figure S1), but
interaction of 14-3-3 with p53 was strongly detectable
only upon drug treatment (Figure 2D). This is probably
due to the elevation of p53 phosphorylation status in
drug-treated cells. However, low levels of p53 could be
immunoprecipitated with g, e, t and s isoform-speciﬁc
antibodies in the absence of drug treatment suggesting
the presence of binding sites in p53 that are constitutively
phosphorylated (Figure 2D). The loss of interaction
between g and e with 3A mutant is not merely due to
the replacement to Ala but rather on their inability to be
phosphorylated which is supported by the following facts
(i) C-terminus of p53 is intrinsically disordered and
mutations to Ala would hardly disrupt the structural
integrity, (ii) the observation that 14-3-3 interacts with
all the single mutants suggests that the Ala replacement
at individual position has no eﬀect and hence would be
collectively inert. It also indicates that phosphorylation at
any one site is suﬃcient to mediate interaction with 14-3-3
e and g, (iii) the observation that e (and g) and s (and t)
interacts diﬀerentially with 3A mutant, strongly supports
that the C-terminus of p53 is the docking site for e (and g)
but probably not for s (and t). If otherwise, binding of
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Figure 1. Thermodynamic studies on 14-3-3 isoforms. (A) Thermal
unfolding of 14-3-3 isoforms was measured using CD by monitoring
the ellipticity at 222nm. The fraction of unfolded protein is plotted as a
function of temperature. Only the s isoform exhibited reversible
folding after denaturation. (B) Isosbestic plot of 14-3-3 s isoform.
Wavelength scans were recorded at diﬀerent temperatures. A sharp
isosbestic point at 205nm is a clear indication of two-state folding.
(C) Thermal denaturation of 14-3-3 isoforms was measured using dif-
ferential scanning calorimetry in a buﬀer containing 20mM HEPES,
150mM NaCl, 3mM DTE, pH 7.2 at a heating rate of 250 C/h.
Table 1. Thermal denaturation of 14-3-3 isoforms
14-3-3 isoforms Tm ( C)
CD (2.5mM) DSC (100mM)
s 64.4±0.4 66.5±0.5
g 62.4±0.6 64.8±0.6
e 60.4±0.3 63.2±0.4
t 58.6±0.4 60.5±0.7
b 57.8±0.7 59.4±0.4
CD data were recorded in a temperature range of 2 Ct o9 8  C with
1 C/min temperature gradient and 4s of response time. For DSC
experiments, a scan rate of 250 C/h was used, over a temperature
range of 10–90 C. Protein samples were measured in a buﬀer contain-
ing 20mM HEPES, 150mM NaCl, 3mM DTE, pH 7.2. The Tm of the
14-3-3 isoforms determined by CD and DSC were compared from each
method separately and showed statistically signiﬁcant diﬀerences
(P < 0.05) except for t with b isoform.
896 Nucleic Acids Research, 2010,Vol. 38,No. 3e (and g) to 3A mutant, as similar to, s (and t) would
be observed, and (iv) the transcriptional activity of p53 (in
the absence of 14-3-3) is unperturbed with all the mutant
proteins, strongly suggesting that the mutations has little
eﬀect on the functional aspect of p53 (Figure 4C).
14-3-3 isoforms bind with varying aﬃnities to the p53 CTD
The in-vivo results indicated that while phosphorylation at
either S366, S378 or T387 is essential for g and e to bind
p53, no such prerequisite seems to exist for t and s.W e
previously reported the binding of p53 CTD mono- or
di-phosphorylated peptides (pS366, pS378 and pT387) to
14-3-3 isoforms g and e. Table 2 lists the peptide sequences
used for binding experiments. Using ﬂuorescence
titrations, we measured the binding aﬃnities for t and s
isoforms to these phosphopeptides (Figure 3) and
compared them with g and e. Table 3 lists the Kds for
the four isoforms that were tested for binding to the
phosphopeptides. t and s isoforms had similar binding
aﬃnities to p53 CTD phosphopeptides. However, the
aﬃnities were weaker and signiﬁcantly diﬀerent from g
and e. This raises the question of the role of t and s
isoforms in regulating the activity of p53 by mediating
interactions with p53 CTD. All the isoforms showed
similar Kds to the mode-2 consensus peptide indicating
that the 14-3-3 isoforms used were functionally active.
Binding of 14-3-3 to p53 CTD wild-type peptide is not
quantiﬁable since no binding was observed (no increase
in polarization) when titrated up to a concentration of
600mM of 14-3-3.
14-3-3 increases the transcriptional activity of p53
We next investigated whether the 14-3-3/p53 inter-
actions plays any role in regulating the transcriptional
activity of p53. Luciferase assays were carried out
in a H1299 cell line with a stably integrated p21-luciferase
reporter gene. Cells were co-transfected with 14-3-3
and p53, followed by CPT treatment. Non-drug treated
cells showed only a marginal increase in transcriptional
activity, which is probably due to the basal phos-
phorylation status of p53 (Supplementary Figure S2).
But, upon drug treatment, the transcriptional activity of
p53 is increased  2.5-fold compared with mock-
transfected cells. Transfection with each of the 14-3-3
isoform resulted in a signiﬁcant increase in p53 activity
as compared with in the absence of 14-3-3 (P<0.05).
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Figure 2. p53/14-3-3 interaction in vitro and in vivo.( A) Phosphorylation status of p53 upon CPT treatment. Immunoprecipitation with pS366-,
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Table 2. Peptides tested for binding to 14-3-3 isoforms
Peptides Sequence*
WT CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS366 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS378 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pT387 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS366/pT387 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS378/pT387 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS366/pS378 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
Mode 2 binding
peptide
ARLYHSLLPAA
Peptides were labelled using ﬂuorescein 50 maleimide at the cysteine
introduced in the p53CTD (362-393) peptides. S and T indicate
phosphorylated serine and threonine, respectively.
Nucleic AcidsResearch, 2010, Vol.38,No. 3 897We also co-transfected the p53 mutants S378A, S366A,
T387A and 3A mutant with 14-3-3 isoforms in separate
experiments. The four isoforms exhibited a similar
increase in the transcriptional activity of p53 S366A,
S378A and T387A mutants. When compared with WT
p53, the diﬀerence in transcriptional activity of these
mutants was negligible, suggesting that the inﬂuence of
14-3-3in p53 activity was not aﬀected by individual
mutations. However, with the 3A mutant, g and e had a
decreased level of transcriptional activity closer to that of
WT p53 in the absence of 14-3-3 (P<0.05), indicating that
these phosphorylation sites are essential for p53 up-
regulation by these isoforms. t and s had no distinguish-
able change in the activity level with the 3A mutant,
indicating that phosphorylation at these sites may not be
necessary for these isoforms to activate p53 (Figure 4A).
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Figure 3. Binding titrations of 14-3-3 t and s and ﬂuorescein-labeled peptides. (A) Binding titration of 14-3-3 t and s to mode-2 consensus peptide.
(B and D) Binding of s isoform to mono- and di-phosphorylated p53 CTD peptides. (C and E) Binding of t isoform to mono- and
di-phosphorylated p53 CTD peptides. Peptides sequences are listed in Table 2. Experiments were carried out at 20 C in 20mM HEPES, 150mM
NaCl, 5mM DTT, pH 7.2. Titrations of g and e to p53CTD phosphopeptides were reported earlier (13).
898 Nucleic Acids Research, 2010,Vol. 38,No. 3Control experiments, transfecting with empty vectors,
were carried out throughout the study. Cells
co-transfected with p53, p53 mutants and empty vector
(14-3-3 insert is absent) showed that the proteins are
over-expressed. Control experiment carried out in the
absence of 14-3-3 showed that the diﬀerences in
transcriptional activity of WT p53 and the p53 mutants
were statistically negligible (Figure 4C). This experiment
conﬁrmed that the mutations introduced had little eﬀect
on the activity of p53. Overall, the results demonstrated
that the presence of 14-3-3 isoforms enhanced
the transcriptional activity of p53. Phosphorylation at
either of the sites S366, S378 or T387 is necessary and
suﬃcient for g and e to activate p53, but is dispensable
for t and s.
q and p isoforms but not c and e leads to increased p53 levels
In order to deduce the possible mechanisms behind the
observed increase in transcriptional activity, p53 levels
have to be monitored inside the cells. To this end, we
used H1299 cell lines that can be induced to stably
express wild-type p53 by tetracycline regulation. In tran-
sient tranfections, the proteins are over-expressed and
hence the levels of p53 cannot be monitored accurately.
Cells were transfected with 14-3-3 isoforms, followed by
induction of p53. The levels of p53 increased in cells
transfected with t and s isoforms and the eﬀect was man-
ifested only in drug-treated cells. On the other hand, no
increase in p53 levels were observed in cells transfected
with either g or e (Figure 5A).
We further validated this observation by transfecting
diﬀerent amounts of 14-3-3 isoforms and looking at the
transcriptional activity and p53 levels. In support of our
earlier observations, p53 levels and hence transcriptional
activity increased with increasing amounts of t and s
isoforms while the transcriptional activity but not p53
levels increased with higher amounts of g and e isoforms
(Figure 5B–D). Although the increase in p53 levels was
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Figure 4. Eﬀect of 14-3-3 isoforms on the transcriptional activity of p53 and various mutants. (A) H1299 cell lines with an integrated p21-luciferase
reporter were co-transfected with 14-3-3 isoforms and p53 (and mutants) in separate experiments, followed by CPT treatment. pcDNA 3.1(+) was
used as a negative control. All the data shown are for drug treated cells. Error bar represents 1 SD for three independent experiments (*P < 0.0.5).
(B) Representative western blot of cell-lysates from H1299 co-transfected with WT p53 or diﬀerent p53 mutants and 14-3-3 g, showed similar protein
levels. Transfections of e, t and s isoforms also showed similar protein levels (Supplementary Figure S3). (C) Control experiments showing luciferase
activity for the wild-type p53 and mutants when co-transfected with empty vectors (in the absence of 14-3-3). (D) Western-blot indicating similar
protein levels of 14-3-3 isoforms in separate experiments is shown.
Table 3. Binding of 14-3-3 isoforms to p53 CTD phosphopeptides
Peptides Kd (mM)
g
a e
a ts
pS366 17±2 16±2 28±3 24±4
pS378 20±2 18±3 27±3 22±3
pT387 14±3 11±2 24±4 23±3
pS366/pT387 0.14±0.07 0.18±0.05 6.2±0.3 3.5±0.4
pS378 /pT387 0.48±0.05 0.51±0.03 2.1±0.4 2.2±0.3
pS378/pT387 0.45±0.03 0.80±0.06 3.3±0.2 7.3±0.3
Consensus peptide 0.43±0.06 0.54±0.01 0.24±0.02 0.12±0.01
WT (362–393) n.q. n.q. n.q. n.q.
The peptides were labeled with ﬂuorescein at the free-amino end of p53
CTD (362–393); n.q., not quantiﬁable
aValues were taken from previously published data (13).
Nucleic AcidsResearch, 2010, Vol.38,No. 3 899not dramatic with t and s isoforms, it is still evident when
compared with g and e which showed constant p53 levels
(Figure 5E). In order to rule out the possibility that t and
s isoforms might introduce any artifactual eﬀect by inter-
acting with components of transcriptional machinery,
H1299 cell-lines that express stable GFP upon induction
was used as a negative control. These cell-lines are
tetracycline-regulated, similar to the H1299 cell-lines
expressing p53 used in this study. The GFP expressing
cell-lines were transfected with all the four isoforms with
and without CPT treatement. From the western blot, it is
evident that 14-3-3 t and s had little eﬀect on GFP levels
indicating that the increase in p53 level observed is 14-3-3
t- and s- speciﬁc (Supplementary Figure S4). The obser-
vation that 14-3-3 t and s stabilize p53 in cells is further
reinforced by the previous report, wherein 14-3-3s was
shown to stabilize p53 by inhibiting its turnover and is
mediated by blocking the activity of MDM2 towards
p53. Hence, in the present study, t and s isoforms
might stabilize p53 either by directly binding to p53 and
preventing degradation or through other mechanisms.
Transfection of empty vectors at increasing amounts
showed no stabilization of p53, further conﬁrming the
observation that the p53 stabilization observed when
transfected with t and s isoforms is t and s-mediated
(data not shown).
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Figure 5. 14-3-3 t and s stabilize p53. (A) H1299 cells expressing inducible p53 were transfected with 14-3-3 isoforms, followed by induction of p53
for 24h (in tet-free medium). p53 induction was stopped by placing the cells in tet-containing medium and cells were treated with 0.5mM CPT or
DMSO (control) for an additional 24h. Cell extracts were prepared and resolved by SDS–PAGE followed by immunoblotting for p53 using
PAb1801 antibody. g and e had no eﬀect on the p53 levels while t and s increased p53 levels. (B) Dose–response luciferase assay for 14-3-3 t
and s is shown. No stimulation of luciferase activity was observed when p53 is not induced. (C) H1299 cells were transfected with increasing
amounts of 14-3-3 t and s. Twenty-four hours post-transfection, cells were lysed and immunoblotted with anti-t, anti-s and anti-p53. A notable
increase in p53 level was observed. (D) Dose–response luciferase assay for 14-3-3 g and e is shown. No stimulation of luciferase activity was observed
when p53 is not induced. (E) Immunoblotting of cell lysates from H1299 cells transfected with increasing amounts of 14-3-3 g and e showed no
pronounced eﬀect on the p53 levels.
900 Nucleic Acids Research, 2010,Vol. 38,No. 3c and e isoforms but not q and p enhance speciﬁc-DNA
binding of p53 in vitro
We previously showed that the g isoform enhanced the
DNA binding activity of p53 in vitro (13). Here we
examined whether e, t and s isoforms had any similar
eﬀects on the DNA binding properties of p53. First, elec-
trophoretic mobility shift assays (EMSA) were carried out
on full-length p53 phosphorylated using Chk1 and Chk2
kinases and increasing amounts of 14-3-3 isoforms: g, e, t
and s and p21 response element (13). In addition to the
previously identiﬁed g isoform, e also enhanced the
speciﬁc-DNA binding of p53 (Figure 6A). The increase
in binding was sequence speciﬁc across diﬀerent lengths
of DNA (Figure 6B). In contrast, t and s isoforms had no
eﬀects on the DNA binding activities of p53 (Figure 6A).
However, the p53-DNA band is super-shifted in the
presence of t and s isoforms indicating ternary complex
formation. Further, the presence of p53 and 14-3-3in the
complex were conﬁrmed by in-gel digestion followed
by mass-spectrometry (Supplementary Figure S5). No
complex formation of 14-3-3 and DNA, in the absence
of p53 was observed, conﬁrming that the stimulation
observed is mediated by activating p53 (Figure 6C).
To determine the DNA binding enhancement
quantitatively, we used our previous approach of ﬂores-
cence titration using ﬂuorescein-labeled p21 response
element (13). The e isoform increased the DNA binding
aﬃnity of p53 to DNA from 48nM to 25nM with the Hill
Constant dropping from  2.1 to 1.2 indicating the
decrease in cooperativity of DNA binding of p53
(Figure 6D). This is similar to the g isoform which we
reported earlier (13). However, in the presence of t and
s isoforms, the Kd of p53 to DNA increased only slightly
to 42nM and the Hill Constant dropped to  1.9 indi-
cating that these isoforms had little eﬀect on the DNA
binding properties of p53 (Figure 6D).
no 14-3-3
τ
σ
γ
no 14-3-3
ε
A
n
i
s
o
t
r
o
p
y
A
n
i
s
o
t
r
o
p
y
[p53 monomer]
A
B
Free DNA
p53/DNA 
p53/DNA/14-3-3
1 2 3 4 5 6 7  8
ε
γ
τ
σ
14-3-3
0.05
0.10
0.15
0.20
0.25
0.08
0.11
0.15
0.19
0.23
0 7.5e-8 1.5e-7 2.3e-7 3e-7
[p53 monomer]
0 7.5e-8 1.5e-7 2.3e-7 3e-7
p53/DNA/14-3-3
p53/DNA 
Free DNA
1 2 3 4 5 6 7   8 9 10
p53
14-3-3
p53
14-3-3
– ––––+ + + + –
–– ––––ε γ γ ε
– – – ––+ + + +
– ε γ τ σ ε γ τ σ
C
D
Free DNA
Figure 6. Eﬀect of 14-3-3 on DNA binding of p53. (A) EMSA experiments carried out with the 14-3-3 isoforms are shown in separate panels.
Lane 1: only DNA (8mM), lane 2-8: p53 (8mM) and increasing amounts of 14-3-3 (0, 2, 4, 8, 10, 15, 20mM, respectively). g and e isoforms showed
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band has disappeared. (C) Control experiment showing no complex formation of 14-3-3 and DNA occurs in the absence of p53. When p53 is present,
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h).
e and g showed a decrease in cooperative DNA binding of p53, while t and s had no pronounced eﬀect.
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We previously identiﬁed that, in addition to the docu-
mented pS378, pS366 and pT387 could serve as additional
interaction sites on p53 with 14-3-3 (13). Here, we report
that (i) 14-3-3 e and g interact with p53, phosphoyrlated at
S366, S378 and T387 in vitro and in vivo, (ii) 14-3-3 t and s
isoforms have additional binding sites in p53, (iii) all the
four isoforms enhances the transcriptional activity of p53,
iv) 14-3-3 t and s increase p53 levels in cells by stabilizing
p53 and (v) 14-3-3 e and g activated p53 for sequence-
speciﬁc DNA binding by stabilizing the tetramer
formation.
First, we measured the thermodynamic stability of the
14-3-3 isoforms to conﬁrm they are properly folded and
stable, before proceeding with further experiments. All ﬁve
isoforms had high values of Tm (Table 1). The s isoform
showed higher thermal stability than other isoforms.
Interaction sites of 14-3-3 on p53
p53 is phosphorylated at S376 and S378 under normal
conditions. Upon IR-treatment, S376 is dephosphory-
lated, creating a 14-3-3 consensus binding site (12). The
14-3-3 family of proteins interacts with various partners
with considerable deviation from the deﬁned canonical
motif (19). Recently, additional 14-3-3 binding sites on
p53 have been proposed based on peptide screening,
where p53 CTD phosphorylated at S366 and T387
bound with similar or higher aﬃnities to 14-3-3 g and e
(13). In the present study, Ni-pull-down assays with 14-3-3
isoforms showed that while s and t interacted with p53
mutated to Ala at either 366, 378, 387 or the triple mutant
3A (366A/378A/387A), g and e failed to interact with 3A
mutant. This observation indicates the possible existence
of other sites of interaction for s and t isoforms. We also
tested the b isoform but it did not show any detectable
binding to wild-type p53 (data not shown). The in vitro
results agreed well with the immunoprecipitation results,
further conﬁrming that phosphorylation at S378 is dis-
pensable for 14-3-3 interactions. Lee et al. (21) have
shown that the phosphorylation status of mouse p53 at
S373 and S375 (human equivalents S376 and S378) is not
essential for 14-3-3 binding. The existence of multiple
binding sites for target binding might act as a fail-safe
mechanism whereby the failure to phosphorylate one
residue is compensated for by phosphorylation at other
sites. A similar mechanism exists for the phosphorylation
sites of the p53 transactivation domain, where multiple
phosphorylations at residues S15, T18, S20 stabilize p53
in cells and prevent MDM2-mediated degradation (5,28).
A 24-fold reduction in MDM2 binding is observed when
the p53 trans-activation domain is phosphorylated at
multiple sites (29).
The interaction of p53 with 14-3-3 isoforms is more
pronounced upon drug (CPT) treatment, indicating that
14-3-3 binding sites (phosphorylated residues) are created
upon DNA damage. CPT induces double-stranded DNA
breaks and activates ATM, which acts upstream in the
activation of the Chk1/Chk2 pathway (30,31). ATM-
dependent dephosphorylation of p53 at S376 and Chk1/
Chk2 dependent phosphorylation of p53 at S378, S366
and T387 generate 14-3-3 binding sites in vivo (10,12).
Inhibition of these kinases aﬀects the phosphorylation
levels of S366 and T387 (10). While CPT has been used
throughout this study to induce DNA damage, use of
other chemotherapeutic agents such as nutlin, cisplatin,
actinomycin D or ionizing radiations might provide
detailed insight into the need of phosphorylation for eﬃ-
cient 14-3-3 interaction at the molecular level.
The in vitro peptide aﬃnity studies carried out in the
present study showed that di-phosphorylated peptides
bound with higher aﬃnity than their mono-phosphory-
lated counterparts in all four 14-3-3 isoforms studied,
suggesting that di-phosphorylated forms of p53 (pS366/
pS378, pS378/pS387, pS366/pT387) may be of biological
importance. This is most likely because 14-3-3 is a dimeric
protein and can simultaneously accommodate two
phospho groups in the binding cavities resulting in a
greater speciﬁcity and higher aﬃnity (16,19); We
previously showed that one 14-3-3 dimer binds one di-
phosphorylated peptide (13). Comparison of the binding
aﬃnities of g and e with t and s to p53 CTD phosho-
peptides revealed that g and e had higher aﬃnities for
mono- and di-phosphopepides. t and s isoforms
showed a 1.7- fold decrease in binding to mono-phos-
phorylated peptides when compared with g and e. The
eﬀect is more pronounced with a 20-fold decrease in
binding to di-phosphorylated peptides. This raised the
question of whether s and t isoforms are directly
involved in regulating p53.
Stavridi et al. (32) have shown that g, e and t isoforms
show IR-speciﬁc interaction with wild-type p53 but s
failed to interact, while Yang et al. (22) reported that
14-3-3 s interacts with p53 and positively regulates the
transcriptional activity of p53. However, we observed
here that all four isoforms interact with p53 but the inter-
action sites are seemingly diﬀerent. The interaction site for
14-3-3 g and e reside in p53 CTD, consistent with the pre-
vious reports (32). s and t isoforms interact with
p53 CTD, albeit with weak aﬃnity as compared to
g and e. Furthermore, the ﬁnding that s and t isoforms
interact with p53 3A mutant in drug-treated cells, strongly
indicates the existence of additional binding sites in
p53. The transactivation domain of p53 (p53 TAD)
is extensively phosphorylated upon DNA damage
(10 phosphorylation sites) and plays a crucial role in
modulating interactions with various targets such as
MDM2, p300 and PC4 (26,29). p53 TAD is the target
for a number of kinases and might create additional
binding sites for s and t isoforms. Using in-vitro peptide
screening, S100 proteins, which were previously known to
interact with the C-terminal domain of p53, has been
shown to interact with p53 TAD (33). Hence, a systematic
screening of various mono-phosphorylated and com-
binations of di-phosphorylated peptides would probably
enable the identiﬁcation of interaction sites of s and t,i f
any, in the p53 transactivation domain. However, it must
be noted that 14-3-3 isoform speciﬁcity is low for the
optimal motifs but much more pronounced towards sub-
optimal motifs, resulting in functional speciﬁcity and
hence, identifying the s and t interaction sites on p53 is
902 Nucleic Acids Research, 2010,Vol. 38,No. 3more challenging and a formidable task, as p53 lacks
optimal binding motif of 14-3-3 (34,35).
Transcriptional activation of p53 by 14-3-3 isoforms
We carried out transcriptional activity assays to study the
eﬀect of 14-3-3 isoforms in regulating the transcriptional
activity of p53. The results clearly demonstrated that all
four isoforms activate p53 transcriptionally. The single
Ala p53 mutants showed a similar activity to wild type
p53 when co-transfected with 14-3-3 g, e, s and t, while
with the 3A mutant, g and e induced a reduction in
transcriptional level close to wild-type p53 only, but s
and t had no such detrimental eﬀect. This observation
further conﬁrmed that phosphorylations at S366, S378
and T387 are dispensable for s and t to activate p53
transcriptionally.
Stabilization of p53 by 14-3-3 p and q
Transcriptional activity of p53 is mainly regulated by
two mechanisms: stabilization leading to increased
p53 levels and activation of p53 for sequence-speciﬁc
DNA binding. Hence, we investigated the mechanism
behind 14-3-3-mediated transcriptional activation of p53.
Transcriptional assays were carried out in H1299 cell-lines
that stably express wild-type p53 under the control of a
tetracycline-regulated promoter. The results clearly
demonstrated that s and t isoforms enhanced the tran-
scriptional activity of p53, by increasing p53 levels,
probably through stabilization. However, no increase in
p53 levels was observed with g and e indicating the stabi-
lization mechanism is isoform-speciﬁc.
Stabilization of p53 in response to DNA damage is
associated primarily with inhibition of MDM2-mediated
degradation. This inhibition is achieved through diﬀerent
routes such as phosphorylation of p53 resulting in reduced
aﬃnity of MDM2 to p53, activation of p19
ARF leading
to inhibition of ubiquitin-ligase activity and regulation
of subcellular localization of MDM2 (36). In an interest-
ing study, Yang et al. (22) have reported that 14-3-3
enhances the transcriptional activity of p53 by increasing
its half-life. Further, 14-3-3 s decreases the half-life of
MDM2 and blocks MDM2-mediated p53 degradation
by inhibiting MDM2’s ubiquitin ligase activity and also
interferes with the nuclear-export activity of MDM2
towards p53 (22). Our results, in general, are consistent
with these observations and, further suggest that in
addition to the previously identiﬁed s isoform, t might
exert a similar regulatory mechanism towards p53.
However, from our results, (i) it is possible that p53
might have additional s and t binding sites, which could
directly interfere with MDM2-mediated degradation, (ii)
these sites are created only upon DNA damage. This
hypothesis is supported by previous report that upon
DNA damage, 14-3-3s stabilize p53 partly by direct
binding and that this characteristic was not observed in
p19
ARF (22). It must be noted that 14-3-3 proteins can also
bind unphosphorylated targets and these targets bind
to 14-3-3 proteins in the same location as phosphorylated
targets (37). Moreover, 14-3-3 s has been shown to have dif-
ferent substrate speciﬁcity in comparison to other isoforms.
Hence, if p53 TAD anchors additional binding sites for s
and t that are created upon DNA damage, it is possible
that binding of s and t to p53 TAD could competitively
inhibit the binding of MDM2 to p53 TAD, resulting in
increased p53 levels, similar to competitive binding of
p300 and MDM2 to p53 TAD (29). While this is specula-
tive at the moment, further experiments to identify s and t
interaction sites on p53 would unravel the stabilization
mechanism behind direct 14-3-3 and p53 interaction.
Perhaps there exist parallel pathways that could also
lead to stabilization of p53 in the presence of 14-3-3.
For instance, 14-3-3 t stabilizes E2F-1 and E2F-1, in
turn, stabilizes p53 by direct binding. Further, E2F-1
upregulates p14
ARF, which negatively regulates
MDM2 (38,39). In a diﬀerent pathway, Akt (protein
kinase B) activation enhances p53 degradation. 14-3-3
s binds and inhibits Akt, resulting in p53 stabilization
(40). Hence, stabilization of p53 by 14-3-3 could be
achieved through diﬀerent pathways. Perhaps, several
other mechanisms of 14-3-3 mediated p53 stabilization
remain unexplored.
Activation of speciﬁc DNA binding of p53 by 14-3-3 c and e
The role of p53 CTD in regulating the sequence-speciﬁc
DNA binding of p53 has been controversial. While
negative regulatory role for p53 CTD has long been
proposed, it has been questioned in the recent years
(41,42). Further, a positive regulatory role of p53 CTD
has been shown for DNA binding and transactivation of
target promoters in vivo. p53 CTD is essential for eﬃcient
sliding along DNA. Importantly, phosphorylation of p53
CTD has little eﬀect on DNA sliding (41). In the context
of short DNA, the stability of sequence-speciﬁc complex is
decreased due to rapid linear diﬀusion of p53 across the
ends. However, in the present study, any inﬂuence of
DNA sliding can be ruled out by the fact the stimulation
of speciﬁc DNA binding of p53 by 14-3-3 was observed
across diﬀerent lengths of DNA (Figure 6B). A positive
regulatory role of phosphorylated p53 CTD can be
derived by its interactions with cofactors such as 14-3-3.
It has been shown that the DNA binding of p53 can be
modulated by co-factors that perturb conformational
equilibrium between dimers and tetramers (43). Invoking
a similar mechanism, activation of speciﬁc DNA binding
can be achieved by regulating the tetramerization of p53.
In our previous study, we proposed a model whereby
14-3-3 g sequesters dimeric p53 to the tetrameric active
DNA binding form (13). p53 exists in equilibrium
between dimers and tetramers at low concentrations.
Binding of two dimers facilitates the sequence speciﬁc
DNA binding of p53 in a co-operative manner (44).
Cofactors like 14-3-3 stabilize the tetrameric form of p53
by shifting the dimer-tetramer equilibrium in favour of
active tetrameric form, resulting in increased DNA
binding. To our knowledge, we were the ﬁrst to demon-
strate previously, using ﬂuorescence aided-Analytical
ultracentrifugation, that 14-3-3 sequesters dimeric p53 to
form tetramers, resulting in reduced co-operativitiy and
increased DNA binding (13). The increase in DNA
binding of p53 (from 44 to 22nM) with a concomitant
Nucleic AcidsResearch, 2010, Vol.38,No. 3 903reduction in Hill Constant (from 2.1 to 1.1) observed here,
in the presence of 14-3-3 g and e, results from stable
tetramer formation of p53. In other words, the dissocia-
tion constant of p53 to dimers and tetramers is decreased
in the presence of 14-3-3.
Previous reports have also made similar observations on
the inﬂuence of tetramerization in activating the sequence-
speciﬁc DNA binding of p53. Deppert and co-workers
(45) showed that Bi-functional redox factor 1 (Ref-1)
enhances the speciﬁc DNA binding of p53 by promoting
association of dimers into tetramers and de-stacking of
higher order oligomers into the tetrameric form.
Acetylation of p53 activates sequence-speciﬁc DNA
binding of p53 and is mediated by promoting
tetramerization (46). In addition, p53b isoform hetero-
tetramerize with wild-type p53 and stimulates it for bax
expression but not p21 (47). BCCIP (BRCA2 and
CDKN1A-interacting protein) enhances transactivation
of p53-target genes by facilitating stable tetramer forma-
tion (48). In an elegant study, c-Abl tyrosine kinase was
shown to interact with p53 CTD and activate DNA
binding by decreasing the dissociation rate of p53–DNA
complex. This activation is independent of its kinase
activity. Interestingly, the interaction of c-Abl with p53
stabilized the tetrameric conformation of p53, leading to
selective stimulation and transactivation of p53 to p21 but
not bax response element (49). While in the present study,
p21 response element was used to study the eﬀect of 14-3-3
on p53, both in vivo and in vitro, it might be interesting to
see if 14-3-3 can exert promoter selectivity for activation
of speciﬁc p53 target genes involved in either growth arrest
or apoptosis, similar to c-Abl.
Role of tetramerization in functional regulation of p53
Tetramerization leads to the most active DNA binding
form of p53 (50). Dimerization of p53 occurs
co-translationally in polysomes while tetramerization
is mediated at post-translational level in solution. It is
proposed that tetramerization of p53 could represent
a form of functional regulation (51). For instance, S100
proteins modulate p53’s response by binding to
monomeric or tetrameric p53, resulting in inhibitory or
stimulatory eﬀect (33). In unstressed cells, the cellular con-
centration of p53 is very low (1–10nM) and may exist
predominantly in monomeric or dimeric forms (49). It is
likely that in response to DNA damage, tetramerization of
p53 is promoted directly by (i) interaction with co-factors
such as BCCIP, c-Abl or Ref-1 and (ii) phoshorylation of
S392 or (iii) in a sequential manner of phosphorylation of
p53 at S366, S378 or T387 followed by 14-3-3-mediated
stable tetramer formation (45,49,52). In this regard, it
might be interesting to see if co-factors such as BCCIP,
c-Abl and Ref-1 regulate tetramerization in a similar
manner as 14-3-3 by reducing the co-operativity of DNA
binding.
CONCLUSIONS
Upon genotoxic stress, two independent events take place.
First, p53 is induced and stabilized, and second, p53
is activated to its functional form leading to cell-cycle
arrest or apoptosis. These events are shown to be indepen-
dent and separable as either stabilization of p53 through
oncogene expression or by the proteosome inhibitor
LLnL, is insuﬃcient to activate p53-dependent cell-cycle
arrest or apoptosis (53,54). In our study, g and e isoforms
but not s and t activated the DNA-binding ability of
p53 in vitro. We and others have shown this eﬀect and
a model has been proposed, whereby 14-3-3 associates
with phosphorylated p53 shifting the dimer-tetramer equi-
librium of p53 to the DNA-binding tetrameric form,
leading to a high aﬃnity complex (12,13). The augmenta-
tion of transcriptional activity of p53 by s and t is
probably mediated by stabilizing p53 levels in cells.
     p53/14-3-3  ,       p53/14-3-3  , 14-3-3 up-regulation
DNA damage
phosphorylated p53
DNA binding activation p53 stabilization
Cell-cycle arrest / apoptosis
Figure 7. Possible role of 14-3-3in the p53 pathway. Upon stress signal, kinases are activated that phosphorylate p53 at multiple sites creating 14-3-3
binding motifs in vivo. p53 is stabilized against MDM2-mediated degradation by 14-3-3 t and s. Isoforms e and g modulate the transcriptional
activity of p53 by stimulating sequence-speciﬁc DNA binding of p53. p53 is stabilized and activated for the transcription of target genes involved in
cell-cycle arrest or apoptotic pathways. 14-3-3 s is a target gene of p53 and is directly involved in cell-cycle arrest, inhibiting G2-M progression.
Further, a positive feedback loop has been proposed for p53 and 14-3-3 s (21,22).
904 Nucleic Acids Research, 2010,Vol. 38,No. 3We propose that 14-3-3 isoforms behave in a functionally
similar way toward p53 but through diverse mechanisms
(Figure 7). One possible reason could be that the 14-3-3
levels are cell-speciﬁc due to its multi-functional roles and
hence diﬀerent mechanisms are exerted towards diﬀerent
targets. The ﬁndings here lead to important questions such
as why 14-3-3 employs diﬀerent regulatory mechanisms
towards p53, although the function is similar, is this
behaviour p53-speciﬁc and more importantly can the
isoforms be swapped for the mechanisms and what are
the determining factors in choosing diﬀerent mechanisms.
The solutions to these questions could potentially shed
more light on the mechanistic preference of other
regulators of p53.
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